Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Screens, lead

It is difficult to obtain accurate particle size analyses of primary expls because (1) consideration and acceptance of necessary safety precautions make the usually tedious job of particle size analysis even more tedious, and (2) many primary expls used in production contain particles which are non-spherical in shape and are in the subsieve size range. Dry screening Lead Azide, for instance, is hazardous and must be done remotely. Furthermore, static charges... [Pg.526]

Keywords VS, Virtual Screening, Lead discovery, lead, HTS, Pharmacophore-Based, Structure-Based, Fragment-based, Ligand-based, Docking, Scoring, hybrid workflows, VS strategy, Benchmarking VS... [Pg.85]

Netzer, R., Ebneth, A., BischofF, U. and Pongs, O. (2001) Screening lead compounds for QT interval prolongation. Drug Discovery Today, 6, 78-84. [Pg.85]

Efforts to find potent and selective DPP-4 inhibitors in the a-amino acid amide series were made in parallel with those in the (3-amino acid amides series. The structural origin of the earliest P-amino acid amide DPP-4 inhibitors traces back to two Merck HTS hits proline derivative 25 and piperazine derivative 26. These two screening leads were further progressed to P-amino acid amide DPP-4 inhibitors incorporating thiazolidine, proline and piperazine amide moieties (Figure 17.5). [Pg.411]

Fig. 18.2 Elaboration-based strategies. Left In SHAPES screening [3], simple drug-like scaffolds are screened using ligand-detected experiments. In the follow-up step, information about binding scaffolds is used to design a follow-up library comprised of analogous compounds. Successive rounds of screening lead to increasingly complex... Fig. 18.2 Elaboration-based strategies. Left In SHAPES screening [3], simple drug-like scaffolds are screened using ligand-detected experiments. In the follow-up step, information about binding scaffolds is used to design a follow-up library comprised of analogous compounds. Successive rounds of screening lead to increasingly complex...
High-throughput screen Lead compound generation... [Pg.60]

Like angiotensin 11, non-peptide B2 receptor antagonists and agonists of bradykinin were obtained by random screening approaches. Chemical modifications on random screening leads like 101 led to non-peptide antagonists... [Pg.38]

Many other non-peptide inhibitors of HIV protease (dihydropyrone, cyclic urea and sulphamide series of compounds) were obtained by modifications of random screening leads. Examples of these include a cyclic sulph-one derivative 147 and 148 (PNU-140690) that showed activity against a variety of HIV t)rpe 1... [Pg.50]

Random screening approaches also provided inhibitors of the enz)nne. SAR studies on the random screening lead Z-His-Tyr(OBn)-Ser(OBn)-Trp-D-Ala-NH2 (PD083176) (IC50... [Pg.53]

A three-peak structure of the carbon Is x-ray photoemission spectrum for CO chemisorbed on Cu (100) is obtained experimentally. The structure is from the photoionization of a carbon Is electron, where three final ion states with roughly the same energies but different degrees of hole screening are excited. These differences in hole-screening lead to the observed differences in the carbon Is binding energies. [Pg.96]

Systemic evaluation of the patient includes a complete blood count, blood chemistry, thiamine level, urinalysis, serum vitamin B12 and folate levels, heavy metal screening (lead, mercury, arsenic), and tests for megaloblastic anemia. The hair may also be tested for indications of toxicity. [Pg.371]

Other type III peptidomimetic inhibitors of thrombin have been developed from screening leads (166, 167) such as inhibitor (94) (Fig. 15.40). SAR led to the design of (95)Inhibitor (96) was derived from docking studies with the 5-amidino indole nucleus, followed by addition of a lipophilic side-chain to interact with the important Sg subsite of thrombin. The crystal structures of both (95) and (96) in the active site of thrombin shows that the aromatic core, binds in the site as expected, but... [Pg.661]

This section illustrates the successful development of non-peptide peptidomimetics from a screening lead by assuming the inhibitor binds to the receptor in the same way as does the native peptide hormone. These assump-... [Pg.667]

Endothelin. The first report of endo-thelin in 1988 stimulated a huge effort to develop selective and non-selective endothelin receptor (ETa and ET ) antagonists (249, 250). One successful approach derived from the postulate that the phenyl groups of the screening lead might mimic two of the aromatic side-chains (Tyr , Phe or Trp ) of... [Pg.672]


See other pages where Screens, lead is mentioned: [Pg.473]    [Pg.755]    [Pg.260]    [Pg.737]    [Pg.737]    [Pg.298]    [Pg.299]    [Pg.32]    [Pg.304]    [Pg.117]    [Pg.48]    [Pg.36]    [Pg.40]    [Pg.12]    [Pg.425]    [Pg.31]    [Pg.755]    [Pg.183]    [Pg.38]    [Pg.189]    [Pg.288]    [Pg.25]    [Pg.74]    [Pg.31]    [Pg.68]    [Pg.164]    [Pg.3]    [Pg.412]    [Pg.635]    [Pg.677]    [Pg.677]    [Pg.2192]   
See also in sourсe #XX -- [ Pg.81 ]




SEARCH



© 2024 chempedia.info